DIRS.INFO The most relevant business & tech news

☆ Moderna stock falls more than 10% as it slashes guidance on low EU sales, tough U.S. vaccine market
▼ + stars: | 2024-08-01 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

It's Moderna's second-ever commercially available product after its Covid vaccine, which has seen demand plunge as the world emerges from the pandemic and relies less on protective shots and treatments. He added that "we've been having quite intense discussions with governments across Europe" to get Covid vaccine supply from Moderna. He is referring to the European Union's massive renegotiated Covid vaccine supply contract with Pfizer and its German partner BioNTech . Its shares are up nearly 20% this year on increasing confidence around its pipeline and messenger RNA platform, which is the technology used in its Covid vaccine and RSV shot. Moderna is also developing a stand-alone flu shot, a personalized cancer vaccine with Merck and shots for latent viruses, among other products.

Persons: It's Moderna's, Stephane Bancel, we've, Bancel, BioNTech, Moderna, I'm Organizations: Moderna Inc, Moderna, Pfizer, GSK, LSEG, Wall, Research, Merck Locations: Cambridge , Massachusetts, Europe, U.S, Moderna, Ukraine

☆ Trump says RFK Jr. is 'not a serious candidate,' refuses to debate him because his numbers are 'too low'
▼ + stars: | 2024-05-02 | by ( Brent D. Griffiths | ) www.businessinsider.com time to read: +4 min

Trump repeatedly attacked Kennedy over social media this past weekend, despite the former president's claim that he knows little about Kennedy. Trump's refusal to debate Kennedy may not be entirely in his hands. But Trump and his allies have been harshly critical of the debate commission. AdvertisementBiden recently told radio host Howard Stern that he would like to debate Trump, but there is rampant speculation such a debate will never occur. The second debate was canceled after Trump refused to accept a virtual format after the then-president tested positive for COVID-19.

Persons: —, Donald Trump, Robert F, Kennedy Jr, Trump, Kennedy, Biden, He's, Nicole Shanahan, MAGA, Joe Biden, Ross Perot, Howard Stern Organizations: Service, RFK, Business, NBC News, Trump voters, Capitol, Politico, Republican National, Texas State University, Trump Locations: Manhattan, Texas, San Marcos , Texas

☆ Lonza’s CEO churn adds to company’s ailments
▼ + stars: | 2023-09-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Denis Balibouse Acquire Licensing RightsLONDON, Sept 18 (Reuters Breakingviews) - Lonza’s (LONN.S) new broom will face even more challenges than its old one. Since he was appointed CEO in 2020, the Swiss group has increased capital expenditure as a percentage of revenue from 20% to 30% last year. Even before Monday’s fall, the stock was trading at 32 times its forward earnings, around the same level as before its pandemic surge. The disruption of another CEO exit, without a clear explanation, means that the hoped-for growth will take even longer to arrive. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias.

Persons: Denis Balibouse, Pierre, Alain Ruffieux, Albert Baehny, Aimee Donnellan, Neil Unmack, Streisand Neto Organizations: REUTERS, Reuters, Swiss, X, Thomson Locations: Lonza, Visp, Switzerland, Swiss

☆ Meet the Black students who were instrumental in developing the first Covid-19 shots
▼ + stars: | 2023-09-15 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +10 min

Among about two dozen scientists in Graham’s lab were three young students: Olubukola Abiona, Geoffrey Hutchinson and Cynthia Ziwawo. What the world didn’t know at the time was that those three students — Abiona, Hutchinson and Ziwawo — were doing the foundational work for those vaccines to eventually save lives. Geoffrey Hutchinson served in the Peace Corps and taught chemistry to high school students in Mozambique. The fruits of Abiona, Hutchinson and Ziwawo’s labor were evident this week as the United States began to roll out updated versions of the Moderna and Pfizer/BioNTech Covid-19 vaccines. Abiona, Hutchinson and Ziwawo all confirmed Wednesday that although they haven’t made their appointments yet, they plan to get the updated shots.

Persons: Barney Graham’s, Olubukola Abiona, Geoffrey Hutchinson, Cynthia Ziwawo, “, Graham, ‘, ’ ”, Hutchinson, ”, ” Ziwawo, Anthony Fauci, — Abiona, Ziwawo —, Ziwawo, Kizzmekia Corbett, ” Corbett, David Satcher, he’s, Valerie Montgomery Rice, “ They’re, Abiona, Hannah Montana, Austin Steele, CNN Abiona, BioNTech, “ It’s, Dr, Sanjay Gupta Organizations: CNN, Vaccine Research, National Institutes of Health, University of Washington, “, Vaccine Research Center, National Institute of Allergy, Diseases, Moderna, Morehouse School of Medicine, David Satcher Global Health Equity Institute, Association of American Medical Colleges, NIH, Disney, David Satcher Global Health Equity Summit, KPMG LLP, Indiana University School of Medicine, Case Western Reserve University, Peace Corps, United States, Pfizer, CNN Health, FDA, Food and Drug Administration, US Centers for Disease Control Locations: China, Bethesda , Maryland, Ziwawo, United States, Atlanta, Graham’s, Nigeria, Mozambique, Abiona, United

☆ Stocks making the biggest moves premarket: Moderna, American, Spirit Airlines, Ford and more
▼ + stars: | 2023-09-13 | by ( Lisa Kailai Han | ) www.cnbc.com time to read: +2 min

A member of the Mississippi National Guard receives a dose of the Moderna Covid-19 vaccine in his arm in Flowood, Mississippi. Moderna — Moderna shares rose more than 3% in early trading after the Centers for Disease Control and Prevention recommended updated Covid vaccine shots for all Americans ages 6 months and older. BP — Shares rose more than 1% before the market open one day after BP CEO Bernard Looney resigned a little more than three years after assuming the post. American Airlines , Spirit Airlines — American Airlines fell 3.1% after lowering its third-quarter earnings guidance, citing higher fuel prices and costs from a new labor agreement. The airline now expects earnings per share in the range of 20 cents to 30 cents, lower than prior guidance of 85 cents to 95 cents.

Persons: Joseph Spak, Spak, Bernard Looney, NIO, —, Samantha Subin, Pia Singh, Sarah Min Organizations: Mississippi National Guard, Moderna, — Moderna, Centers for Disease Control, Pfizer, Apple, Apple Watch, Ford —, UBS, BP, Union, American Airlines, Spirit Airlines — American Airlines Locations: Flowood , Mississippi, U.S, NIO —

☆ CDC advisors recommend updated Covid vaccines for all Americans ages 6 months and up
▼ + stars: | 2023-09-12 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

An independent advisory panel to the Centers for Disease Control and Prevention on Tuesday recommended that all Americans ages 6 months and up receive updated Covid vaccines from Pfizer and Moderna , the next step toward the shots reaching Americans in the coming days. Thirteen advisors voted in favor of that "universal" recommendation for Americans, while one voted against it. It is a vaccine-preventable disease," said Dr. Beth Bell, clinical professor at the University of Washington and member of the panel, during the advisory meeting. "And so, for that reason, I favor the universal recommendation." The advisory panel's "universal" recommendation comes a day after the Food and Drug Administration approved the two mRNA jabs, which are designed to target the omicron subvariant XBB.1.5.

Persons: Mandy Cohen, Georgina Peacock, Beth Bell, Hospitalizations, hospitalizations, Megan Wallace Organizations: Moderna, Pharmacy, Centers for Disease Control, Pfizer, CDC, University of Washington, Food and Drug Administration, FDA Locations: Schwenksville , Pennsylvania, U.S

☆ Moderna, Pfizer say updated COVID shots generate strong response vs newer variant
▼ + stars: | 2023-09-06 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

Moderna said its shot generated an 8.7-fold increase in neutralizing antibodies against BA.2.86 compared with an untreated natural antibody response in clinical trials in humans. Pfizer said its updated vaccine with partner BioNTech (22UAy.DE) elicited a strong antibody response against BA.2.86 in a preclinical study in mice. Moderna, Pfizer/BioNTech and relative newcomer to the COVID vaccine market Novavax (NVAX.O) have created versions of their shots aimed at the XBB.1.5 subvariant, the dominant variant through most of 2023. Moderna shares were down 1.6% and Pfizer shares were off nearly 3% in afternoon trading. The Omicron offshoot carries more than 35 mutations in key portions of the virus compared with XBB.1.5, the target of the updated shots.

Persons: Moderna, Jacqueline Miller, BioNTech, Cowen, Tyler Van Buren, Dado Ruvic, Patrick Wingrove, Michael Erman, Bill Berkrot Organizations: Pfizer, World Health Organization, WHO, U.S . Centers for Disease Control, Prevention, ” Moderna, Moderna, REUTERS, CDC, Omicron, U.S . Food, Drug Administration, Britain's Medicines, Healthcare, Agency, Reuters, Thomson Locations: Switzerland, South Africa, Israel, Denmark, U.S, Britain, New York, New Jersey

☆ Moderna's updated COVID vaccine effective against 'Eris' variant in humans
▼ + stars: | 2023-08-17 | by ( ) www.reuters.com time to read: +2 min

Vials of the Moderna COVID-19 vaccine are seen at Apotex pharmaceutical company as Humber River Hospital's mobile vaccine clinic vaccinate employees as part of the coronavirus disease (COVID-19) vaccination campaign, in Toronto, Ontario, Canada April 13, 2021. REUTERS/Carlos Osorio/File Photo Acquire Licensing RightsCompanies BioNTech SE FollowModerna Inc FollowNovavax Inc Follow Show more companiesAug 17 (Reuters) - Moderna (MRNA.O) said on Thursday an initial study data showed its updated COVID-19 vaccine to be effective against the "Eris" and "Fornax" subvariants in humans. Moderna and other COVID-19 vaccine makers Novavax (NVAX.O), Pfizer (PFE.N) and German partner BioNTech SE (22UAy.DE) have created versions of their shots aimed at the XBB.1.5 subvariant. Earlier on Thursday, Pfizer reported that its updated COVID-19 shot, co-developed with BioNTech, showed neutralizing activity against the Eris subvariant in a study conducted on mice. Eris, the nickname for EG.5, is similar to the XBB.1.5 subvariant and a sub-lineage of the still-dominant Omicron variant.

Persons: Carlos Osorio, BioNTech, Pratik Jain, Shilpi Majumdar Organizations: Moderna, REUTERS, Pfizer, EG, Omicron, World Health Organization, Thomson Locations: Humber, Toronto , Ontario, Canada, United States, Europe, U.S, Bengaluru

☆ Dolly Parton says she 'never' wants to retire: 'I'll just hopefully drop dead on stage'
▼ + stars: | 2023-07-17 | by ( Morgan Smith | ) www.cnbc.com time to read: +2 min

"I'll just hopefully drop dead in the middle of a song on stage someday, hopefully one I've written." But, Parton said, a few things could convince her to stop working after 60-plus years in the music industry. "As long as I'm able to work, as long as my health is good, and my husband is good," she said. "I have new dreams every day … I've got lots of dreams," Parton said of her future aspirations, noting that she wants to have her own network television show, as well as her own makeup and wig lines. Part of what motivates Parton to keep working, she added, is wanting to see all of her professional goals through to the end.

Persons: Dolly Parton, she'd, Parton, I'm, she's, Tony, Dolly, I've, you've Organizations: Grand Ole Opry, Foundation, Imagination, Moderna

☆ Moderna strikes deal to develop mRNA drugs in China
▼ + stars: | 2023-07-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Moderna on Wednesday said it struck a deal with Chinese officials to research, develop and manufacture messenger RNA medicines in the country, despite rising tensions between the U.S. and China. The Massachusetts-based biotech company signed a memorandum of understanding and a related land collaboration deal to develop drugs that will "be exclusively for the Chinese people" and won't "be exported," a Moderna spokesperson told CNBC. The Moderna spokesperson did not confirm the report or comment on the size of the deal. Moderna in May said it was keen to sell its mRNA Covid vaccine to China after registering a legal entity in the world's second-largest economy. The country has also struggled to develop mRNA technology at home during the pandemic.

Persons: Stéphane Bancel, It's, drugmakers, Biden Organizations: Moderna, U.S, CNBC, The Moderna, Pfizer, China's Ministry of Commerce, AstraZeneca, Novo Nordisk, Merck, Sanofi, GE HealthCare Technologies Locations: China, The Massachusetts, Shanghai, Japan, Canada, Australia, Kenya, Beijing, New York

☆ Moderna's billionaire CEO draws criticism for earning nearly $400 million in stock options last year, and then getting a raise on top of it
▼ + stars: | 2023-04-29 | by ( Jordan Hart | ) www.businessinsider.com time to read: +3 min

French businessman Stéphane Bancel made $393 million in stock options in 2022, according to securities filings. Bancel, 50, also owns stocks valued around at least $2.8 billion, and received a 50% raise from 2021 to 2022. Moderna's chief executive officer Stéphane Bancel raked in about $393 million in 2022 thanks to stock options, and then received a raise on top of it — compensation that's giving some analysts pause. In addition to exercising his stock options in 2022, 50-year-old Bancel earned a $1.5 million salary — a 50% jump from 2021, according to securities filings from March. Meanwhile, Amazon CEO Andy Jassy's pay dropped from $212 million in 2021 to $1.3 million in 2022 due to receiving any stock awards.

☆ Fact Check-COVID ‘monovalent’ vaccines not banned, FDA approval not withdrawn
▼ + stars: | 2023-04-25 | by ( Reuters Fact Check | ) www.reuters.com time to read: +6 min

But the original vaccines remain licensed in the United States and are not “banned” as suggested by some social media users. An FDA spokesperson also commented on the agency’s official Twitter account: “It's probably worth clarifying that the monovalent vaccines are still approved (licensed). EUA information for the Moderna and Pfizer vaccines can be seen on the FDA website (here) , (here). The FDA withdrew authorizations for emergency use of Pfizer-BioNTech and Moderna monovalent COVID vaccines while authorizing use of the updated, bivalent versions in all age groups. The agency did not withdraw its approval or license of the original vaccines, nor “ban” their use.

Mohawk Industries — Shares of the flooring manufacturer gained 5% after Loop Capital upgraded the company to buy from its previous hold rating. WisdomTree — Shares of the financial firm gained 3% after the company said it had $1.9 billion of net flows in March. New York Community Bancorp — Shares of the regional bank gained 2.7% after Jefferies upgraded the stock to buy from hold. LendingClub — The lending stock gained 5% after JPMorgan initiated coverage of the stock at overweight. Murphy Oil — The natural gas company's shares gained 2.6% after Truist upgraded shares to buy from hold.

☆ Deutsche Bank sees more than a 30% rally for this specialty biotech stock
▼ + stars: | 2023-04-10 | by ( Brian Evans | ) www.cnbc.com time to read: +3 min

Deutsche Bank is more bullish on Catalent after the New Jersey-based company expanded its manufacturing partnership with Moderna . Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. CTLT YTD mountain Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share. Catalent shares were upgraded to buy from hold on Monday, with a price target of $88 per share, Deutsche Bank said. Stock Chart Icon Stock chart icon Catalent received an upgrade from Deutsche Bank on Monday from hold to buy with a price target of $88 per share.

☆ Moderna says it hopes to offer new vaccines for cancer, heart disease, and other conditions by 2030
▼ + stars: | 2023-04-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Moderna hopes to offer a new set of life-saving vaccines targeting cancer, heart disease and other conditions by 2030, a spokesperson for the company told CNBC on Monday. "It can be applied to all sorts of disease areas; we are in cancer, infectious disease, cardiovascular disease, autoimmune diseases, rare disease." Burton's remarks also come ahead of Moderna's Vaccine Day on Tuesday. He highlighted Moderna's personalized cancer vaccine, a highly anticipated mRNA shot being developed to target different tumor types. In February, the Food and Drug Administration granted Breakthrough Therapy Designation to Moderna's personalized cancer vaccine in combination with Merck's immunotherapy drug Keytruda for patients with a deadly form of skin cancer called melanoma.

☆ China OKs its first mRNA vaccine, from drugmaker CSPC
▼ + stars: | 2023-03-22 | by ( ) www.reuters.com time to read: +2 min

BEIJING, March 22 (Reuters) - China's CSPC Pharmaceutical Group Limited (1093.HK) said on Wednesday its messenger RNA (mRNA) COVID-19 vaccine had received emergency use authorisation from Chinese health authorities, making it the country's first domestically developed mRNA shot. China has declined to use mRNA vaccines from abroad and vaccines available in China are widely considered less effective than the Moderna (MRNA.O) and Pfizer (PFE.N)-BioNTech (22UAy.DE) mRNA shots. The company said its independently developed mRNA vaccine SYS6006 targets some major Omicron variants and its booster dose showed good neutralization effect against Omicron subvariants BA.5, BF.7, BQ.1.1., XBB.1.5 and CH.1.1. The firm got emergency approval to conduct clinical trials of the mRNA shot in April last year, around the same time as CanSino, another China-based company that is testing an mRNA Omicron booster shot. Shares in the company rose as much as 7.7% after the result and the announcement of the mRNA approval.

☆ Moderna expects to price its COVID vaccine at about $130 in the US
▼ + stars: | 2023-03-21 | by ( Patrick Wingrove | ) www.reuters.com time to read: +2 min

REUTERS/Hannah BeierMarch 20 (Reuters) - Moderna Inc (MRNA.O) expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday. Hoge said the government's Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine. Sanders, chair of the Senate’s powerful Health, Education, Labor and Pensions Committee, has said Moderna should not raise the price of its vaccine because of the government funding it received. He plans to question Moderna Chief Executive Stephane Bancel on the price increase at the hearing on Wednesday. Moderna in February forecast significantly declining 2023 COVID-19 vaccine sales, which reached $18.4 billion in 2022.

☆ Moderna shares pop 7% after Cowen upgrades stock, saying it 'will be a leader' in RSV vaccines
▼ + stars: | 2023-03-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Moderna shares jumped by nearly 7% on Wednesday after TD Cowen upgraded the stock, saying the company will "be a leader" in the RSV vaccine market. Cowen pointed to the company's potential RSV vaccine, noting that key opinion leaders believe RSV will be a "three-player vaccine market" between Moderna and drugmakers Pfizer and GSK. Moderna's RSV vaccine performed well in clinical trials and was well tolerated by patients, the note said. Moderna's RSV vaccines for adults ages 60 and older received Breakthrough Therapy Designation from the Food and Drug Administration in late January. Cowen noted that Moderna believes the regulatory support of its competitors' RSV candidates "should read-through" to its own.

☆ Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand
▼ + stars: | 2023-02-23 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Moderna on Thursday missed earnings expectation for the fourth quarter, as costs rose from surplus production capacity and lower demand for its Covid-19 vaccine, the company's only product on the market. Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share. Moderna has signed contracts for $5 billion in Covid vaccine deliveries for 2023. Moderna estimates U.S. market volume in fall 2023 will be 100 million doses, said Arpa Garay, the company's chief commercial officer. Garay said Moderna will leverage the infrastructure it already has in place for Covid to launch the RSV vaccine.

☆ Moderna CEO Stephane Bancel will testify before Senate next month on Covid vaccine price hike
▼ + stars: | 2023-02-15 | by ( Spencer Kimball | ) www.cnbc.com time to read: +3 min

Moderna CEO, Stephane Bancel attends 2019 Forbes Healthcare Summit at the Jazz at Lincoln Center on December 05, 2019 in New York City. Moderna CEO Stephane Bancel will testify before the Senate health committee in March over the company's plans to hike the price of its Covid-19 vaccine. Sanders, in a letter to Bancel last month, slammed the proposed price hike as "outrageous" given that the vaccine was developed in cooperation with the National Institutes of Health using taxpayer money. When the federal supply runs out, uninsured adults may have to pay the full price for the shots. There is a federal free vaccine program for children whose families or caretakers can't afford the shots.

☆ Walmart, CVS Health adjust pharmacy hours amid labor crunch
▼ + stars: | 2023-01-27 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Mike Segar/File PhotoJan 27 (Reuters) - Walmart Inc (WMT.N) said on Friday it would adjust working hours for its U.S. pharmacy team and implement it nationwide in 4,600 locations, with drugstore operator CVS Health Corp (CVS.N) doing the same for about two-thirds of its retail pharmacies, amid a tight labor market. The United States has been experiencing a nationwide labor shortage since the COVID-19 pandemic which has forced retailers to offer attractive incentives and pay increases. Earlier on Friday, the Wall Street Journal first reported CVS Health Corp and Walmart were cutting pharmacy hours. CVS said the new hours of operation, which begin in March, at impacted pharmacies will vary, adding it periodically reviews operating hours to make sure peak customer demand was being met. Walgreens said in a statement that at times it had to adjust store or pharmacy hours at some places after staffing challenges impacted retailers and healthcare entities, among others, over the last 12 months.

[1/2] A logo is pictured on the Ibex building of Lonza, where the Moderna mRNA coronavirus disease (COVID-19) vaccine will be produced, in Visp, Switzerland, September 29, 2020. REUTERS/Denis Balibouse/File PhotoJan 25 (Reuters) - Lonza (LONN.S) on Wednesday said it will buy back shares worth 2 billion Swiss francs ($2.17 billion), despite an expected drop in annual margins, as the Swiss drug contract manufacturer backed its growth prospects for the near future. Lonza expects its 2023 core earnings before interest, depreciation and amortization, or EBITDA margin, to slip between 30% and 31%, down from 32.1% in 2022, as last year's boost from COVID-19 vaccine manufacturing services waned. The Basel-based company, however, reiterated a target of 33%-35% for 2024 marginsand announced a 17% rise in its annual dividend. The Swiss group forecast sales growth in the "high single-digit" adjusted for currency swings, a slow-down from the 15.1% rise it saw last year.

☆ Moderna, Pfizer's new race: The RSV vaccine FDA approval process
▼ + stars: | 2023-01-18 | by ( Eric Rosenbaum | ) www.cnbc.com time to read: +8 min

Both companies have released results from RSV vaccine trials with efficacy results strong enough to expect expedited approval from the FDA. The companies — which have been involved in litigation brought by Moderna alleging mRNA patent infringement, a claim Pfizer disputes — are both expected the FDA approval process for the RSV vaccine to occur soon. We can use the same, the same equipment and raw materials as the Covid vaccine." The RSV approval process is just one part of a widening vaccine industry for these two companies. "Every strain is treated as suspicious and we start working on it to see if it can overcome the vaccine," Bourla said.

☆ Stocks making the biggest moves premarket: United Airlines, Moderna, IBM and more
▼ + stars: | 2023-01-18 | by ( Samantha Subin | ) www.cnbc.com time to read: +3 min

United Airlines – Shares of United Airlines rose 3.5% after the company reported quarterly earnings that topped Wall Street's estimates for the fourth quarter, signaling strong demand amid higher prices. United posted adjusted earnings per share of $2.46 on $12.4 billion in revenue. Analysts expected adjusted earnings per share of $2.10 and $12.2 billion in revenue, per Refinitiv. Analysts surveyed by StreetAccount had anticipated adjusted earnings of $2.44 per share on revenues of $3.81 billion. PNC reported $3.49 in adjusted earnings per share on $3.68 billion of revenue.

☆ Sen. Sanders asks Moderna not to hike COVID vaccine price
▼ + stars: | 2023-01-10 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

[1/5] Boxes containing the Moderna COVID-19 vaccine are prepared to be shipped at the McKesson distribution center in Olive Branch, Mississippi, U.S. December 20, 2020. Senator Bernie Sanders sent Moderna Inc (MRNA.O) a letter this week asking the drug company to halt planned U.S. price increases on its COVID-19 vaccine, saying price hikes could make the shot unaffordable for millions of Americans. Sanders said in his letter that raising prices would be particularly egregious after the U.S. government provided around $1.7 billion to fund development of the vaccine. The Vermont senator has railed against high drug prices and backed Medicare-for-all, and his chairmanship of the HELP committee could put drug companies in his crosshairs. Moderna's COVID-19 vaccine sales were around $18.4 billion in 2022.

Search resuls for: "The Moderna"

25 mentions found